Dernières nouvelles pour Polyrizon (NASDAQ:PLRZ) Stock

Polyrizon

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Polyrizon Ltd

Macro Economic Events

Economics

Federal Reserve

Powell Says Feels Good About Where The Economy Is, Expects Another Good Year Next Year

<p><strong>Nike Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) will likely provide more color on what the future looks like under new CEO <strong>Elliot Hill </strong>when the apparel and footwear company reports second-quarter financial results after <a href="https://www.benzinga.com/earnings">the market closes on Thursday.</a></p>
<p><strong>Earnings Estimates</strong>: Analysts expect Nike to report second-quarter financial revenue of $12.13 billion. That&#8217;s down from $13.39 billion in last year's second quarter, according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1">from Benzinga Pro.</a></p>
<p>The company has missed analyst revenue estimates in two straight quarters and four of the last five quarters. Over the last 10 quarters, Nike beat analyst revenue estimates six times.</p>
<p>Analysts expect the company to report second-quarter earnings per share of 64 cents. That&#8217;s down from $1.03 per share in last year's second quarter. The company has beaten analyst estimates for earnings per share in five straight quarters and nine of the last 10 quarters.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/12/42443622/nikes-nfl-partnership-gets-a-major-boost-with-10-year-deal-stock-gains">Nike&#8217;s NFL Partnership Gets Major Boost With 10-Year Deal, Stock Gains</a></strong></p>
<p><strong>What Analysts Are Saying: </strong>Traffic and promotion trackers could signal a mixed second quarter from Nike, according to Goldman Sachs analyst Brooke Roach, who has a Buy rating and $97 price target.</p>
<p>Promotionality remains a key item to watch in the report,  Roach said in a new investor note.</p>
<p>"On balance, our conversations with investors have been more muted on the stock in recent weeks, and our trackers largely demonstrate missed trends in F2Q," Roach said.</p>
<p>Commentary from retail partners suggests higher promotional activity during the holiday season and higher inventory levels, Roach said.</p>
<p>"We believe that recent data points suggest that it is still early in Nike's turnaround journey, and that we have yet to see signs of material brand heat improvement."</p>
<p>The focus in Wednesday's report will likely center on the future path to stronger innovation and top-line growth, Roach added.</p>
<p>Roach said they were looking forward to hearing from Hill in his fist official quarter. The 30-year Nike vet rejoined the company and became CEO on Oct. 14.</p>
<p>"We believe Mr. Hill will provide initial commentary around the forward strategy of the company including any material changes to his approach."</p>
<p>Telsey analyst Cristina Fernandez also shared a desire to hear about Nike's product innovation pipeline and new plans from Hill.</p>
<p>The analyst maintained an Outperform rating on Nike and lowered the price target from $96 to $93.</p>
<p>"Overall, Nike is in a period of transition and a return to growth could take a few quarters," Fernandez said in a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42515463/nike-needs-a-turnaround-after-q2-results-are-released-this-week-will-new-ceo-just-do-it">recent investor note</a>.</p>
<p>The analyst said the Nike turnaround could take around a year to show changes play out.</p>
<p>Here are other <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">analyst ratings on Nike</a> and their price targets:</p>
<ul>
<li>Wells Fargo: Maintained Overweight rating, lowered price target from $95 to $92</li>
<li>Evercore ISI: Maintained Outperform rating, lowered price target from $105 to $97</li>
<li>Deutsche Bank: Maintained Buy rating, lowered price target from $92 to $82</li>
<li>Morgan Stanley: Maintained Equal-Weight rating, lowered price target from $82 to $80</li>
</ul>
<p><strong>Key Items to Watch:</strong> All eyes and ears will be on Hill when the company reports results Thursday.</p>
<p>One item to watch could be the company's focus on value or being a premium brand and product.</p>
<p>A recent YouGov 2024 value <a href="https://commercial.yougov.com/rs/464-VHH-988/images/WP-2024-12-US-Value-Rankings-Report.pdf">survey</a> showed that Nike was the biggest gainer in the most improved score as a better deal in 2024 versus 2023 with an 8.5-point gain year-over-year. The survey suggests that consumers see Nike products as more affordable compared to what they were years ago or in comparison to peer brands.</p>
<p>Nike will likely not comment on President-elect <strong>Donald Trump</strong>&#8216;s threat to impose tariffs on China. The company could be asked about this impact by analysts as many other companies have <a href="https://www.benzinga.com/trading-ideas/24/12/42536470/costco-warns-that-tariffs-raise-prices-trump-team-says-trade-policies-will-make-life-affordable">in recent weeks.</a></p>
<p>Investors might also focus on the geographical breakdown of revenues in the quarter. The<a href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale"> last quarterly report</a> showed overall revenue down 10% year-over-year with North America being one of the weakest regions at -11% year-over-year. China sales, by comparison, were down 4% year-over-year.</p>
<p><strong>Price Action:</strong> Nike stock is up 0.4% to $78.33 on Wednesday versus a 52-week trading range of $70.75 to $123.39. Nike stock is down 26% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42145065/nikes-worst-may-nearly-be-over-says-analyst-hailing-new-ceo-elliott-hill-as-proverbial-white-knight-for-brand-recovery">Nike&#8217;s Worst May Nearly Be Over: Analyst Sees CEO Transition And Strategic Fixes Sparking A Turnaround</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Price Target

Reiteration

Analyst Ratings

Trading Ideas

Nike Q2 Earnings Preview: Analyst Says Athletic Brand Early In 'Turnaround Journey' With New CEO

News

Legal

US Prosecutors Announce Lawsuit Accusing CVS Of Filling And Billing Us Government For Unlawful Opioid Prescriptions

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>American Express</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXP, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for American Express.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $54,200, and 6 are calls, for a total amount of $449,370.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $350.0 for American Express over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for American Express options trades today is 1054.86 with a total volume of 112.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for American Express's big money trades within a strike price range of $240.0 to $350.0 over the last 30 days.</p>
<h3>American Express Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552629_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$27.9</td>
<td>$26.9</td>
<td>$27.2</td>
<td>$300.00</td>
<td>$133.2K</td>
<td>579</td>
<td align="right">51</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$59.1</td>
<td>$57.55</td>
<td>$59.15</td>
<td>$270.00</td>
<td>$130.1K</td>
<td>1.3K</td>
<td align="right">22</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$53.5</td>
<td>$52.45</td>
<td>$52.91</td>
<td>$260.00</td>
<td>$68.7K</td>
<td>3.5K</td>
<td align="right">13</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$64.0</td>
<td>$62.8</td>
<td>$62.8</td>
<td>$240.00</td>
<td>$62.8K</td>
<td>248</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$29.6</td>
<td>$29.25</td>
<td>$29.25</td>
<td>$280.00</td>
<td>$29.2K</td>
<td>83</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About American Express</h3>
<p>American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.</p>
<p>Following our analysis of the options activities associated with American Express, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is American Express Standing Right Now?</h3>
<ul>
<li>With a volume of 1,212,434, the price of AXP is down -1.51% at $296.79. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About American Express</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $329.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Keefe, Bruyette &amp; Woods keeps a Outperform rating on American Express with a target price of $350.<br />
&#x2A; An analyst from Keefe, Bruyette &amp; Woods persists with their Outperform rating on American Express, maintaining a target price of $350.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on American Express, maintaining a target price of $301.<br />
&#x2A; Maintaining their stance, an analyst from Compass Point continues to hold a Neutral rating for American Express, targeting a price of $315. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for American Express, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

American Express Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Walmart</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WMT, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 27 uncommon options trades for Walmart.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $130,170, and 24 are calls, for a total amount of $1,644,031.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $46.67 to $130.0 for Walmart over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Walmart's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walmart's whale activity within a strike price range from $46.67 to $130.0 in the last 30 days. </p>
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552624_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$95.00</td>
<td>$344.7K</td>
<td>5.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.6</td>
<td>$4.55</td>
<td>$4.55</td>
<td>$95.00</td>
<td>$121.4K</td>
<td>5.4K</td>
<td>730</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.6</td>
<td>$4.55</td>
<td>$4.55</td>
<td>$95.00</td>
<td>$111.4K</td>
<td>5.4K</td>
<td>113</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.3</td>
<td>$8.25</td>
<td>$8.3</td>
<td>$90.00</td>
<td>$104.5K</td>
<td>5.8K</td>
<td>131</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.35</td>
<td>$5.3</td>
<td>$5.35</td>
<td>$95.00</td>
<td>$98.9K</td>
<td>4.4K</td>
<td>323</td>
</tr>
</tbody>
</table>
</p>
<h3>About Walmart</h3>
<p>Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.</p>
<h3>Current Position of Walmart</h3>
<ul>
<li>Currently trading with a volume of 9,141,913, the WMT's price is down by -0.42%, now at $95.02. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 64 days.</li>
</ul>
<h3>Professional Analyst Ratings for Walmart</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $99.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Walmart with a target price of $96.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Walmart, which currently sits at a price target of $94.<br />
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Walmart, targeting a price of $96.<br />
&#x2A; An analyst from Jefferies persists with their Buy rating on Walmart, maintaining a target price of $111.<br />
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Walmart, which currently sits at a price target of $100. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Walmart, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In WMT Options

<p>High-rolling investors have positioned themselves bullish on United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in UAL often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for United Airlines Holdings. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 50% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $47,520, and 7 calls, totaling $326,610.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $120.0 for United Airlines Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for United Airlines Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Airlines Holdings's whale activity within a strike price range from $70.0 to $120.0 in the last 30 days. </p>
<h3>United Airlines Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552619_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.55</td>
<td>$5.5</td>
<td>$5.55</td>
<td>$97.50</td>
<td>$110.0K</td>
<td>2.1K</td>
<td align="right">223</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.65</td>
<td>$2.62</td>
<td>$2.65</td>
<td>$95.00</td>
<td>$57.7K</td>
<td>8.7K</td>
<td align="right">241</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.0</td>
<td>$21.6</td>
<td>$21.6</td>
<td>$105.00</td>
<td>$47.5K</td>
<td>102</td>
<td align="right">0</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$21.0</td>
<td>$20.65</td>
<td>$20.85</td>
<td>$85.00</td>
<td>$41.7K</td>
<td>646</td>
<td align="right">20</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$120.00</td>
<td>$30.5K</td>
<td>596</td>
<td align="right">94</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Airlines Holdings</h3>
<p>United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.</p>
<h3>Current Position of United Airlines Holdings</h3>
<ul>
<li>With a trading volume of 2,215,623, the price of UAL is down by -0.15%, reaching $94.84.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>What The Experts Say On United Airlines Holdings</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $129.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on United Airlines Holdings with a target price of $125.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on United Airlines Holdings, maintaining a target price of $130.<br />
&#x2A; An analyst from UBS has revised its rating downward to Buy, adjusting the price target to $139.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on United Airlines Holdings, which currently sits at a price target of $122. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Airlines Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


United Airlines Holdings Options Trading: A Deep Dive into Market Sentiment

<p>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 7.93% on an annualized basis producing an average annual return of 21.15%. Currently, Krystal Biotech has a market capitalization of $5.04 billion. </p>
<p><strong>Buying $100 In KRYS:</strong> If an investor had bought $100 of KRYS stock 5 years ago, it would be worth <strong>$274.71</strong> today based on a price of $176.51 for KRYS at the time of writing.</p>
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552614_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KRYS

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Powell Says Hiring Rate Is Low, Which Is A Sign Of Softening; Says Level Of Unemployment Is Low And Participation Is High

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Powell On Bitcoin Reserve, Says We Are Not Allowed To Own Bitcoin And Not Looking For A Law Change

LNZA

Technip Energies And LanzaTech Secure $200M U.S. DOE Funding To Advance CO2-To-Ethylene Technology With Initial $20M For Phase 1 Engineering And Community Engagement

Powell Says Labor Market Not Cooling In A Way That Raises Concerns

<p>Across the recent three months, 11 analysts have shared their insights on Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Nevro, presenting an average target of $5.34, a high estimate of $7.00, and a low estimate of $4.00. Experiencing a 21.35% decline, the current average is now lower than the previous average price target of $6.79. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552064_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Nevro is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.70</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.89</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nevro. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nevro compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Nevro's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nevro's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVRO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nevro analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Nevro</h2>
<p>Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.</p>
<h3>Understanding the Numbers: Nevro's Finances</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Nevro faced challenges, resulting in a decline of approximately <strong>-6.69%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Nevro's net margin excels beyond industry benchmarks, reaching <strong>-15.83%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-5.6%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Nevro's ROA excels beyond industry benchmarks, reaching <strong>-2.56%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Nevro's debt-to-equity ratio is below the industry average. With a ratio of <b>0.9</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVRO

Where Nevro Stands With Analysts

<p>In the latest quarter, 6 analysts provided ratings for DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.33, a high estimate of $107.00, and a low estimate of $84.00. This current average has increased by 0.17% from the previous average price target of $94.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552053_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive DuPont de Nemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$84.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DuPont de Nemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DuPont de Nemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for DuPont de Nemours's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DuPont de Nemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DuPont de Nemours analyst ratings.</strong></a></p>
<h2>Get to Know DuPont de Nemours Better</h2>
<p>DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to separate the company into three companies going forward, one focused on electronics, one focused on water, and one with more diversified end market exposure. We expect the separations will occur by mid-2026.</p>
<h3>DuPont de Nemours: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, DuPont de Nemours showcased positive performance, achieving a revenue growth rate of <strong>4.38%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> DuPont de Nemours's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>14.22%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> DuPont de Nemours's ROE excels beyond industry benchmarks, reaching <strong>1.91%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> DuPont de Nemours's ROA excels beyond industry benchmarks, reaching <strong>1.23%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.29</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying DuPont de Nemours: Insights From 6 Analyst Reviews

<p>4 analysts have shared their evaluations of FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated FMC and provided 12-month price targets. The average target is $68.25, accompanied by a high estimate of $81.00 and a low estimate of $55.00. This current average has decreased by 3.42% from the previous average price target of $70.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552043_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive FMC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Parkinson</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$67.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FMC. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FMC compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into FMC's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FMC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on FMC analyst ratings.</strong></a></p>
<h2>About FMC</h2>
<p>FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.</p>
<h3>FMC's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> FMC's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>8.5%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> FMC's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.08%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> FMC's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> FMC's ROA excels beyond industry benchmarks, reaching <strong>0.53%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> FMC's debt-to-equity ratio surpasses industry norms, standing at <strong>0.88</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For FMC

<p>Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $319.65, a high estimate of $350.00, and a low estimate of $270.00. Marking an increase of 6.35%, the current average surpasses the previous average price target of $300.56. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552034_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Monday.Com's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Lucky Schreiner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Iwanyc</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$340.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Connor Murphy</td>
<td>Capital One</td>
<td>Announces</td>
<td>Overweight</td>
<td>$325.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$327.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Monday.Com. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Monday.Com compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Monday.Com's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Monday.Com's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MNDY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Monday.Com analyst ratings.</strong></a></p>
<h2>Discovering Monday.Com: A Closer Look</h2>
<p>Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.</p>
<h3>Monday.Com's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Monday.Com showcased positive performance, achieving a revenue growth rate of <strong>32.67%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Monday.Com's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-4.79%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.28%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Monday.Com's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.79%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Monday.Com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.09</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MNDY

17 Analysts Assess Monday.Com: What You Need To Know

<p>During the last three months, 4 analysts shared their evaluations of Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Treace Medical Concepts and provided 12-month price targets. The average target is $7.6, accompanied by a high estimate of $8.40 and a low estimate of $6.00. This upward trend is evident, with the current average reflecting a 6.0% increase from the previous average price target of $7.17.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552024_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Treace Medical Concepts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.40</td>
<td>$7.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Treace Medical Concepts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Treace Medical Concepts compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Treace Medical Concepts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Treace Medical Concepts's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TMCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Treace Medical Concepts analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Treace Medical Concepts</h2>
<p>Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.</p>
<h3>Unraveling the Financial Story of Treace Medical Concepts</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Treace Medical Concepts displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.62%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Treace Medical Concepts's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-34.07%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Treace Medical Concepts's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-14.15%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-7.0%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Treace Medical Concepts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.67</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TMCI

Deep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings)

Powell Says It Might Take Another Year Or Two From Here To Get To 2%

<p>8 analysts have shared their evaluations of MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.38, along with a high estimate of $55.00 and a low estimate of $43.00. Surpassing the previous average price target of $49.14, the current average has increased by 4.56%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734552013_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of MPLX among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MPLX. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MPLX compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for MPLX's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MPLX's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MPLX analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind MPLX</h2>
<p>MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.</p>
<h3>Breaking Down MPLX's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> MPLX displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.28%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>37.14%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MPLX's ROE excels beyond industry benchmarks, reaching <strong>7.52%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MPLX's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.68%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> MPLX's debt-to-equity ratio is below the industry average at <strong>1.66</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MPLX

What Analysts Are Saying About MPLX Stock

Powell Says Housing Inflation Has Come Down Steadily,  Goods Inflation Has Returned To Pre-Pandemic Range Overall

<p><em>Editor's Note: The spelling of Michael Saylor&#8217;s name has been corrected in the headline.</em></p>
<p>Financial market commentator <strong>Peter Schiff</strong> on Tuesday criticized <strong>Michael Saylor&#8217;s </strong>comparison of <strong>MicroStrategy Inc.</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-financed <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy to Manhattan real estate.</p>
<p><strong>What Happened</strong>: In an X post, Schiff disagreed with Saylor&#8217;s analogy. &#8220;Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#8217;t generate any income to make interest or principal payments,&#8221; he argued.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">It&#39;s wrong for <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> to compare his leveraged buying of <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> to investors borrowing money to purchase Manhattan real estate. Real estate generates rents, which can be used to service and repay debt. Bitcoin doesn&#39;t generate any income to make interest or principal payments.</p>
<p>&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1869116244714262623?ref_src=twsrc%5Etfw">December 17, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Spencer Hakimian</strong>, founder of hedge fund <strong>Tolou Capital Management</strong>, countered Schiff&#8217;s viewpoint, stating that, unlike the Manhattan real estate industry, Bitcoin doesn&#8217;t have any expenses or maintenance.</p>
<p>Schiff responded that rents from real estate exceed the expenses.</p>
<p>The city&#8217;s rental market contradicts national trends, with the top 50 markets experiencing 15 consecutive months of rent decreases. In October 2024, New York&#8217;s <a href="https://www.benzinga.com/real-estate/24/12/42256888/as-nyc-rents-hit-new-highs-85-of-residents-look-to-buy-elsewhere-heres-what-they-find">median asking rent</a> increased 1.7% year-on-year to $3,374, representing a 13.1% increase from pre-pandemic values. Manhattan&#8217;s median monthly rent stood at $4,750 as of this writing, according to Realtor.com.</p>
<p><strong>See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42544639/moonpay-partners-with-element-wallet-to-boost-core-token-access-in-btcfi-ecosystem">MoonPay Partners With Element Wallet To Boost Core Token Access In BTCfi Ecosystem</a></strong></p>
<p><strong>Why It Matters</strong>: This criticism comes after Saylor defended MicroStrategy&#8217;s Bitcoin acquisition strategy by equating it to Manhattan&#8217;s real estate industry. He said that <a href="https://www.benzinga.com/24/12/42524546/michael-saylor-counters-critics-who-label-microstrategys-bitcoin-play-ponzi-scheme-calls-it-similar-to-manhattans-real-estate-developers-using-debt-to-build-more-skyscrapers">just like developers in Manhattan issue more debt </a>to develop more real estate when its value goes up, MicroStrategy capitalizes on high returns from Bitcoin to buy more Bitcoin.</p>
<p>Schiff&#8217;s critique adds to the ongoing debate around MicroStrategy&#8217;s Bitcoin strategy. Earlier, he <a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy">warned that the</a> company's commitment to repay a large sum of money to convertible note holders could be a potential risk if the price of Bitcoin falls sharply.</p>
<p>Well-known cryptocurrency analyst <strong>Willy Woo</strong> also <a href="https://www.benzinga.com/24/11/42228264/crypto-analyst-flags-convertible-debt-induced-liquidation-risk-to-michael-saylors-microstrategy">flagged the risk </a>associated with the firm&#8217;s convertible debt offerings, stating that if buyers do not convert to shares&nbsp;before maturity, MicroStrategy would be forced to sell Bitcoin to repay them.</p>
<p><strong>Price Action</strong>:&nbsp; At the time of writing, Bitcoin was exchanging hands at $105,351.94, down 0.86% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. </p>
<p>Shares of MicroStrategy closed 5.41% lower at $ 386.42 during Tuesday&#8217;s regular session. The stock has a <a href="https://www.benzinga.com/quote/MSTR">consensus price target </a>of $449.5 based on the ratings of 12 analysts, with an average price target of $546.67 between&nbsp;<strong>Bernstein</strong>,&nbsp;<strong>TD Cowen</strong>, and&nbsp;<strong>Barclays</strong>.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42538636/pudgy-penguin-token-launches-at-2-billion-valuation-could-land-between-shiba-inu-and-dogecoin-trader-says">Pudgy Penguin Token Launches At $2 Billion Valuation, Could Land &#8216;Between Shiba Inu And Dogecoin,&#8217; Trader Says</a></strong></li>
</ul>
<p><em>Image via Flickr/ Gage Skidmore</em></p>


MSTR

Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: 'BTC Doesn't Generate Any Income' (CORRECTED)

The deal size was increased to 959K shares of common stock from 808K shares of common stock and the range was $4.38-$6.02. Aegis acted as sole book...

Polyrizon 959K share IPO priced at $4.38

Polyrizon (PLRZ) priced 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share a...

Polyrizon opens at $1.64, IPO priced at $4.38 per unit

Polyrizon and Gelteq made their public debut on Tuesday in a quiet Halloween week for the IPO market. LATEST IPOS AND DIRECT LISTINGS: Polyrizon (P...

Opening Day: Polyrizon, Gelteq debut in quiet IPO week

Heritage Distilling, Ming Shing and Dynamix made their public debut as the IPO market cools off ahead of Thanksgiving week in the U.S. LATEST IPOS ...

Opening Day: Heritage Distilling, Dynamix open for trading

Heritage Distilling, Ming Shing, and Dynamix all made a public debut as the IPO market has cooled off ahead of Thanksgiving week in the U.S.

Heritage Distilling, Dynamix Open For Trading

The company states: "Polyrizon (PLRZ) Ltd. announces the signing of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading E...

Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker

Polyrizon (PLRZ) previously announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a leading European-based G...

Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial

ADBE

CAMP

CASK

CBLL

CLIK

DYNX

GELS

PLRZ

SKYQ

STFS

IPOs

Press Releases

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker "PLRZ"

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Health Care

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Bionomics Limited - American Depository Shares

Bionomics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Carmell

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

GT Biopharma

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Moleculin Biotech

Oragenics

Onconetix

Organovo Holdings

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Windtree Therapeutics, Inc. - Common Stock

Comments

Polyrizon

Actualités

Dernières nouvelles pour Polyrizon (NASDAQ:PLRZ) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL